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A B S T R A C T
Disruption of the cooperative balance between osteoblasts and osteoclasts causes various bone disorders, some
of which are because of abnormal osteoclast recruitment. Osteoporosis, one of the bone disorders, is not
eﬀectively treated by currently available medicines. In addition to the development of novel drugs for palliative
treatment, the exploitation of novel compounds for preventive treatment is important in an aging society.
Quercetin, a major ﬂavonoid found in many fruits and vegetables, has been expected to inhibit cancer and
prevent several diseases because of its anti-inﬂammatory and estrogenic functions. It has been reported that
quercetin has the potential to reduce bone resorption, but the mechanism by which this compound aﬀects the
diﬀerentiation of osteoclasts remains unknown. Here, using a bone marrow cell-based in vitro osteoclast
diﬀerentiation system from bone marrow cells, we found that the ability of quercetin to inhibit osteoclastogen-
esis was related to its estrogenic activity. The inhibition was partially blocked by a speciﬁc antagonist for the
nuclear receptor estrogen receptor α, but a speciﬁc antagonist of the membrane-type receptor GPR30
completely ablated this inhibition. Furthermore, quercetin suppressed the transient increase of Akt phosphor-
ylation induced by the stimulation of macrophage colony-stimulating factor and receptor activator of NF-κB
ligand with no eﬀect on MAPK phosphorylation, suggesting exquisite crosstalk between cytokine receptor and
G-protein coupled receptor signaling. These results indicate the important role of GPR30 in osteoclast
diﬀerentiation and provide new insights to the development of new treatments for osteoporosis.
1. Introduction
Osteoclasts are primary cells responsible for bone resorption, and
these cells are of hematopoietic stem cell origin. Precursors of
osteoclasts have been demonstrated to share properties with the
monocyte/macrophage cell lineage [1,2]. Since the receptor activator
of NF-κB ligand (RANKL) was discovered as an essential cytokine for
osteoclast diﬀerentiation in the presence of macrophage colony-stimu-
lating factor (M-CSF) [3–5], the molecular mechanisms of osteoclast
diﬀerentiation and function have been extensively studied [6]. Drugs
developed in these studies are expected to cure bone diseases such as
bone metastasis, osteopetrosis, and osteoporosis; some of these drugs
are currently in use [7].
In particular, osteoporosis is a disease for which treatments have
become more important in an aging society for reasons such as
increasing population of elderly patients and the close relationship of
osteoporosis to the quality of life of patients. Disruption of the balance
between bone formation by osteoblasts and bone resorption by
osteoclasts results in osteoporosis. Treatments for osteoporosis include
vitamin D3, calcium, and estrogen supplementation as well as bispho-
sphonates and anti-RANKL antibody administration [8]; various
compounds are expected to have eﬃcacy, particularly as preventive
treatments.
Flavonoids are a class of the compounds expected to have pre-
ventive eﬀects against osteoporosis [9]. They are secondary metabolites
of plants and the most common group of polyphenols in the human
diet. In plants, they are important for guarding against oxidant damage
and attacks by insects and microbes. In humans, many beneﬁts of
ﬂavonoids related to metabolic syndrome, cancer, brain health, and
immune system have been suggested by recent researches. Quercetin is
a major ﬂavonoid found in many fruits and vegetables, including onion,
caper, and apple; ﬂavonoids may have preventive eﬀects against some
http://dx.doi.org/10.1016/j.bbrep.2016.10.013
Received 17 May 2016; Received in revised form 5 September 2016; Accepted 24 October 2016
⁎ Corresponding author.
E-mail address: tomsato@dent.kagoshima-u.ac.jp (T. Sato).
Abbreviations: RANKL, receptor activator of NF-κB ligand; M-CSF, macrophage colony-stimulating factor; QOL, quality of life; GPCR, G-protein coupled receptor; BMC, bone
marrow cell; TRAP, tartrate-resistant acid phosphatase
Biochemistry and Biophysics Reports 8 (2016) 389–394
2405-5808/ © 2016 The Authors. Published by Elsevier B.V. This is an open access article under the  CC BY-NC-ND license (http://creativecommons.org/licenses/by/4.0/).
Available online 03 November 2016
crossmark
diseases and inhibitory eﬀects against some cancers [10,11]. These
properties have been considered to be attributable to its anti-inﬂam-
matory or anti-oxidant action, but recent studies suggest that quercetin
has further eﬀects such as estrogenic activity [12].
Several studies illustrated that quercetin reduced bone resorption
by suppressing the diﬀerentiation of osteoclasts [13–15]. In these
studies, NF-κB, AP-1 [14], and NFATc1 [15] were involved in the
eﬀects of quercetin, whereas the eﬀects on the estrogen receptor (ER)
were controversial. These genes are known as the master genes of
osteoclastogenesis, and it may be a natural consequence that these
genes are aﬀected by the suppression of osteoclast diﬀerentiation.
Moreover, the receptors to which quercetin binds are unknown.
Examination of these receptors and the downstream signal transduc-
tion is important to elucidate the precise mechanisms of the eﬀects of
quercetin.
In this study, we demonstrate the eﬀect of quercetin on osteoclas-
togenesis using an in vitro osteoclast diﬀerentiation system using bone
marrow-derived monocytes/macrophages. Suppression of osteoclast
diﬀerentiation partially recovered because of ERα antagonism and
entirely because of GPR30 antagonism. The membrane-type G-protein
coupled receptor (GPCR) GPR30 was constantly expressed during
osteoclast diﬀerentiation, and the suppression of this diﬀerentiation
by a GPR30 agonist was similar to the suppression by quercetin. Signal
molecule analysis revealed that quercetin and a GPR30 agonist
suppressed the phosphorylation of Akt. Thus, the results of this study
indicate the importance of GPCR signaling in addition to the cytokine
signals, such as M-CSF and RANKL in osteoclast cells.
2. Materials and methods
2.1. Reagents and antibodies
Quercetin was purchased from Wako Pure Chemical (Osaka,
Japan). The classical ERα/β antagonist ICI182,780, the GPR30 agonist
G-1, and the GPR30 antagonist G-15 were purchased from Tocris
Bioscience (Bristol, UK).
Anti-phospho-Akt, anti-Akt, anti-phospho-MAPK, and anti-MAPK
antibodies were purchased from Cell Signaling Technology (Danvers,
MA). Anti-β-actin antibody and HRP-conjugated anti-rabbit antibody
were purchased from IMGENEX (San Diego, CA) and Santa Cruz
Biotechnology (San Diego, CA) respectively.
2.2. In vitro osteoclastogenesis
Bone marrow-derived monocyte/macrophage osteoclast precursors
were isolated as described previously [16,17]. Brieﬂy, bone marrow
cells (BMCs) were ﬂushed out from the bone marrow cavity of the
femora and tibiae of 4–12-week-old C57BL/6 J male mice (Kyudo,
Tosu, Japan) and suspended in α-MEM (Wako) supplemented with
10% fetal bovine serum (FBS; Nichirei, Tokyo, Japan), 100 U/ml
penicillin, and 20,000 U/ml Leukoprol (Kyowa, Tokyo, Japan) as a
source of M-CSF and cultured for 3 days in Petri dishes in a humidiﬁed
atmosphere of 5% CO2. Then, after the removal of nonadherent cells
and stromal cells by washing with PBS and by subsequent incubation
for 5 min in 0.25% Trypsin/ 0.05% EDTA, the monocytes/macro-
phages were harvested in α-MEM/10% FBS by vigorous pipetting. The
isolated monocytes/macrophages were seeded as osteoclast progeni-
tors and cultured in α-MEM /10% FBS with M-CSF (equivalent of 20
ng/ml) and recombinant mouse soluble RANKL (sRANKL, 10 ng/ml,
Wako) and/or other agents. The culture medium was exchanged every
2 days.
After culturing, osteoclasts were ﬁxed in methanol and stained for
tartrate-resistant acid phosphatase (TRAP) activity using a leukocyte
acid phosphatase kit (Sigma-Aldrich, St. Louis, MO) according to the
manufacturer's instructions. The TRAP activities of osteoclasts were
measured with 20 μl of culture medium incubated for 4 min at 37 °C
with 80 μl of buﬀer (40 mM NaCl, 4 mM EDTA, 0.2% Triton X-100,
400 mM acetic acid, 1.76 mg/ml L-ascorbic acid, 9.2 mg/ml sodium
tartrate dihydrate, 3.6 mg/ml p-nitrophenylphosphate disodium) and
terminated by the addition of 100 μl of 300 mM NaOH; the absorbance
at 405 nm was measured using a Multiskan FC plate reader (Thermo
Fischer Scientiﬁc, Waltham, MA).
Animal experiments were conducted in accordance with the in-
stitutional guidelines of Kagoshima University for the care and use of
experimental animals and approved by the Animal Research
Committee of Kagoshima University.
2.3. Semi-quantitative RT-PCR
Total RNA was extracted with Sepazol RNA I Super G (Nacalai
Tesque, Kyoto, Japan), and 0.1 μg of the total RNA was used as a
template for cDNA synthesis with a ReverTraAce qPCR RT Kit
(Toyobo, Osaka, Japan). The sequences of the primers used for PCR
were as follows:
GPR30 forward 5′-TGGTCCTTGTTTTCTTCATCTGCTG-3′ and re-
verse 5′-CACAGCACTGCTGAACCTGACCTCT-3′;
ERα forward 5′-CAGGGAGAAGAGTTTGTGTGCCTCA-3′ and re-
verse 5′-TCAGATCGTGTTGGGGAAGCCCTCT-3′;
ERβ forward 5′-GATGAGGGGAAGTGCGTGGAAGGGA-3′ and re-
verse 5′- TCACTGTGACTGGAGGTTCTGGGAG-3′;
β-actin forward 5′-TCACCCACACTGTGCCCATCTAC-3′ and reverse
5′-GAGTACTTGCGCTCAGGAGGAGC-3′.
2.4. Western blot analysis
After various stimulations, the cells were washed twice with cold
PBS and extracted in lysis buﬀer [50 mM Tris–HCl (pH 7.5), 150 mM
NaCl, 1% Nonidet P-40, 0.1% sodium deoxycholate, 1 mM sodium
ﬂuoride, 1 mM sodium vanadate, and a protease inhibitor cocktail
(Nacalai Tesque)]. The extracts were centrifuged at 13,000 rpm for
10 min, and the supernatants were used for analysis. Samples contain-
ing equal amounts of protein were subjected to SDS-PAGE, and the
proteins separated in the gel were electrotransferred onto polyvinyli-
dene diﬂuoride membranes. After blocking with 5% skim milk, the
membrane was immunoblotted with the indicated antibodies, and
subsequently with peroxidase-conjugated anti-rabbit IgG antibody.
Immunoreactive proteins were visualized with Chemi-Lumi One
Super (Nacalai Tesque) according to the manufacturer's instructions.
2.5. Statistical analyses
Statistical analyses were performed using SPSS Statistics (IBM).
Data were analyzed by one-way analysis of variance followed by Tukey
post hoc tests. For all graphs, data are shown as means ± standard
deviation (SD). Statistical signiﬁcance is indicated as follows: *, p <
0.01; **, p < 0.05.
3. Results
3.1. Inhibition of osteoclast diﬀerentiation by quercetin
To examine the role of quercetin in osteoclastogenesis, we ﬁrst
cultured osteoclast precursors with sRANKL and quercetin at several
concentrations. As shown in Fig. 1A, when osteoclast precursors were
cultured with sRANKL in the absence of quercetin, TRAP-positive
mononuclear preosteoclasts appeared on day 2 and began to fuse with
each other to form multinucleated osteoclasts on days 3–4. In contrast,
quercetin addition decreased the number of TRAP-positive multi-
nucleated cells in a concentration-dependent manner. For more
detailed analysis, we measured TRAP activity in the culture medium.
Quercetin addition also decreased TRAP activities in the culture
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Fig. 1. Suppression of in vitro osteoclastogenesis in the presence of quercetin. A. Osteoclast precursors obtained from bone marrow cells treated with macrophage colony-stimulating
factor (M-CSF) for 3 days were cultured with quercetin at the indicated concentrations in the presence of M-CSF (20 ng/ml) and soluble receptor activator of NF-κB ligand (sRANKL)
(10 ng/ml) for 3 days. After culturing, the cells were stained for tartrate-resistant acid phosphatase (TRAP) activity. B. Osteoclast precursors were cultured as indicated in A. TRAP
activity in the culture medium was measured (mean ± SD of four experiments; *, p < 0.01 vs. positive control containing sRANKL without quercetin). C. Osteoclast precursors were
cultured under diﬀerentiation conditions with 10 μM quercetin and 1 μM tamoxifen (Tam) or 1 μM ICI182,780 (ICI) for 3 days. After culturing, TRAP activity in the culture medium was
measured [mean ± SD of six experiments; *, p < 0.01 vs. RANKL (+), quercetin (+), and antagonist (−)].
Fig. 2. Involvement of GPR30 in osteoclastogenesis. A. Bone marrow-derived monocyte/macrophage osteoclast precursors were cultured with macrophage colony-stimulating factor
(M-CSF; 20 ng/ml) and soluble receptor activator of NF-κB ligand (sRANKL; 10 ng/ml) for the indicated periods with the ascertainment of osteoclast maturation at day 4. The
expressions of GPR30, ERα, ERβ, and β-actin were determined by semi-quantitative RT-PCR in which the respective cDNAs were not saturated. B. Osteoclast precursors were cultured
with M-CSF, sRANKL and the indicated concentration of G-1, a speciﬁc agonist of GPR30. Following osteoclast maturation, tartrate-resistant acid phosphatase (TRAP) activity in the
culture medium was measured (mean ± SD of four experiments; *, p < 0.01 vs. cells cultured without G-1).
M. Masuhara et al. Biochemistry and Biophysics Reports 8 (2016) 389–394
391
medium (Fig. 1B). Compared with the control, TRAP activities
decreased by 35, 70, and 83% in the presence of 2, 5, and 10 μM of
quercetin, respectively.
Many studies reported that quercetin has anti-oxidant activity,
although estrogenic eﬀects have also been reported in recent studies
[12,18]. There is no information regarding the estrogenic activity of
quercetin in osteoclast cells; thus, we assessed whether quercetin
functioned as an estrogenic agent in osteoclastogenesis using ER
antagonists. As observed in Fig. 1A-B, osteoclast precursors were
cultured with quercetin and/or the ER antagonists tamoxifen and
ICI182,780 (Fig. 1C). There were no signiﬁcant eﬀects between
tamoxifen or ICI182,780 and positive controls in the TRAP assay.
TRAP activity decreased by quercetin addition, and this decline did not
recover by tamoxifen addition. Upon the addition of another antago-
nist, ICI182,780, the decrease in TRAP activity recovered (p < 0.01) but
the recovery was only partially (approximately 38%).
3.2. Expression and function of the membrane-type ER GPR30 in
osteoclasts
As tamoxifen and ICI182,780 antagonized the activities of estrogen,
particularly its nuclear receptors ERα and ERβ, and partially reversed
the eﬀects of quercetin, we examined the involvement of another ER,
GPR30/GPER1, in osteoclastogenesis. Carmeci et al. identiﬁed that
GPR30 is a GPCR [19], and Heino et al. reported its expression in bone
tissue [20]. As the expression proﬁle of GPR30 during osteoclast
diﬀerentiation has not been reported, we examined the expression of
GPR30. Osteoclast precursors were cultured with M-CSF and sRANKL;
samples were prepared sequentially for semi-quantitative RT-PCR to
determine the expression of GPR30, ERα, ERβ and β-actin. As
observed for ERα, GPR30 was constantly expressed throughout the
osteoclastogenesis (Fig. 2A). ERβ expression was not observed, in
accordance with the lack of the role of ERβ in osteoclast function [21].
With the observation of GPR30 expression during osteoclastogen-
esis, we subsequently examined the involvement of GPR30 in osteo-
clastogenesis. As illustrated in Fig. 1, osteoclast precursors from BMCs
were diﬀerentiated in the presence of the speciﬁc GPR30 agonist G-1.
Similar to the case of quercetin, TRAP activity in the culture medium
decreased by the addition of G-1 (Fig. 2B), with signiﬁcant loss of
multinucleated mature osteoclasts (data not shown). It is noteworthy
that the diﬀerentiation was inhibited by a remarkably low concentra-
tion of a speciﬁc GPR30 agonist, suggesting the participation of GPR30
in osteoclastogenesis.
3.3. Eﬀect of quercetin via GPR30 in osteoclasts
These results revealed that osteoclastogenesis was suppressed by
both quercetin and a GPR30 pathway. Next, we analyzed whether
quercetin suppressed the diﬀerentiation of osteoclasts via the GPR30
signaling pathway using its speciﬁc antagonist G-15. There was no
signiﬁcant eﬀect of G-15 alone on the positive control (Fig. 3A).
However, the addition of G-15 clearly reversed the suppression
induced by quercetin (Fig. 3B), demonstrating that the direct binding
of quercetin to GPR30 is important for osteoclastogenesis. TRAP
images of the recovery eﬀect by G-15 are shown in the lower part of
Fig. 3B.
3.4. Signals from GPR30 in osteoclast precursors
Since the identiﬁcation of the master cytokine, RANKL [3], and the
master transcription factor, NFATc1 [22], the mechanisms by which
many signal molecules regulate various processes have been elucidated.
However, signals from GPCRs in osteoclasts remain unknown. To
disclose the mechanism by which the signal pathway in osteoclastogen-
esis was inﬂuenced by GPR30, we examined the activation of Akt and
MAPK, which are involved in important signaling pathways in osteo-
clast diﬀerentiation and survival. To examine the molecular mechan-
isms in osteoclastogenesis, we cultured preosteoclasts with M-CSF and
RANKL for 2 days.
The preosteoclasts were starved in serum free medium for 3 h and
stimulated by M-CSF and sRANKL with or without quercetin. As
shown in Fig. 4A, temporal phosphorylation of Akt and MAPK were
observed upon stimulation in the absence of quercetin. The addition of
quercetin resulted in the disappearance of the transient phosphoryla-
tion of Akt with no or a modest eﬀect on MAPK. Moreover quercetin
suppressed the baseline level phosphorylation of Akt at 60 min. This
result suggested the possibility that the phosphorylation of Akt in
response to cytokine signaling was impaired by GPCR signaling.
As previously mentioned, quercetin inhibited the osteoclastogenesis
via GPR30 signaling. To conﬁrm the involvement of GPR30 in the
action of quercetin, we analyzed Akt phosphorylation using GPR30
antagonists and agonists. Preosteoclasts cultured with M-CSF and
RANKL were stimulated with or without quercetin and GPR30 ligands
for 15 min. As shown in Fig. 4B, similar to quercetin, the GPR30
agonist suppressed Akt phosphorylation. Further, the GPR30 antago-
nist G-15 rescued the quercetin-induced suppression of Akt phosphor-
Fig. 3. Reversal of quercetin-induced suppression of osteoclastogenesis by a speciﬁc
GPR30 antagonist. A. Bone marrow-derived monocyte/macrophage osteoclast precur-
sors were cultured with macrophage colony-stimulating factor (M-CSF; 20 ng/ml) and
soluble receptor activator of NF-κB ligand (sRANKL; 10 ng/ml) with or without G-15
(10 µM), a speciﬁc antagonist of GPR30. B. Preosteoclasts treated as described in A were
cultured with or without quercetin (5 μM) and G-15 (10 μM). Following osteoclast
maturation, tartrate-resistant acid phosphatase (TRAP) activity in the culture medium
was measured (mean ± SD of eight experiments; **, p < 0.05), and the images of the
TRAP stain are shown in the lower parts of B.
M. Masuhara et al. Biochemistry and Biophysics Reports 8 (2016) 389–394
392
ylation. In contrast, the phosphorylation of MAPK was not changed in
any case. Taken together, the abovementioned results obtained in this
study suggest that quercetin inhibited osteoclastogenesis via GPR30,
and that the phosphorylation of Akt is involved in this activity.
4. Discussion
In this study, we demonstrated that quercetin suppressed osteo-
clastogenesis induced by RANKL from osteoclast precursors in a
concentration-dependent manner. We particularly focused on the
estrogenic activity of quercetin and found that the suppression of
osteoclastogenesis was not completely reversed by ERα and ERβ
antagonists but by an antagonist for the novel membrane-type ER
GPR30. GPR30 was expressed during osteoclastogenesis, and a GPR30
agonist suppressed osteoclastogenesis in a manner similar to that of
quercetin but at an extremely low concentration. Moreover, a GPR30
antagonist reversed the inhibition induced by quercetin, reinforcing
our hypothesis that quercetin functions via the GPR30 pathway in
osteoclastogenesis. Our analyses of signal molecules indicated that Akt
phosphorylation was inhibited by the addition of quercetin and a
GPR30 agonist, suggesting that Akt participates in the quercetin-
mediated suppression of osteoclastogenesis. Ford et al. described the
involvement of GPR30 on bone mineralization by using Gpr30 knock-
out mice, but they reported no information about the mechanism of
signal transduction [23], and the function of GPR30 remains unre-
solved. In fact, Martensson et al. demonstrated that deletion of GPR30
reduced bone growth but reported that there was no eﬀect on the
skeleton of male mice [24]. Additionally, Windahl et al. showed that
estrogen treatment had no eﬀect of reduced growth plate height on
Gpr30 KO mice [25]. Our in vitro results together with their in vivo
studies help to clarify the functions of GPR30.
GPR30 is a member of the GPCR family [19], which is considered as
the most successful target for the drug discovery. Garland described in
his review that the analyses of approved drugs typically quote 30% to
50% of all medications as exerting their eﬀects via members of this
family [26]. He also noted that GPCRs are still a mainstay for new
drugs, as seen by examination of recent regulatory approvals in the
United States. There were 21, 30, and 39 new molecular entities
approved by the Food and Drug Administration in 2010, 2011, and
2012, respectively. Of these, 5 of 21 (2010), 5 of 30 (2011), and 7 of 39
(2012) target GPCR, giving a total of 17 of 90 (19%) over the 3 years.
Despite the importance of drug exploitation for osteoporosis, studies of
the roles of GPCRs in osteoclasts have not advanced, excluding studies
on parathyroid hormone and calcitonin, which are the essential
hormones for bone metabolism. The crucial participation of RANKL,
a TNF family cytokine, in osteoclastogenesis has been indicated in
several studies; however, as revealed in our results, the additional
signals from other receptors must not be ignored.
Osteoporosis is a disorder caused by an imbalance between bone-
forming osteoblasts and bone-resorbing osteoclasts. In the treatment of
osteoporosis, bisphosphonates are frequently administered as they are
the inhibitors of osteoclast functions. Regardless of their beneﬁts, in a
subset of patients receiving these drugs, osteonecrosis of the jaws has
emerged as a signiﬁcant complication [27]. Osteonecrosis induced by
the adverse eﬀect of bisphosphonates is called bisphosphonate-related
osteonecrosis of the jaw (BRONJ). The inhibition of osteoclast function
can also inhibit normal bone turnover, preventing local microdamage
from normal mechanical loading or injury being repaired; this ulti-
mately results in bone necrosis. The complete blockage of osteoclasto-
genesis may be an etiology of BRONJ; thus the mild regulation of
osteoclasts such as that by quercetin may be important for the
treatment of osteoporosis.
In addition to palliative treatment, preventive care is also important
for osteoporosis. Regarding preventive care, agents with few harmful
actions are required. In this context, ﬂavonoids such as quercetin have
useful characteristics. As more studies investigate the functions of
ﬂavonoids in other cell types, their usefulness will increase. It is desired
that the eﬀects of ﬂavonoids are comprehensively assessed in all cell
types. In this study, we could not show direct binding of quercetin to
GPR 30, though it has been reported that quercetin stimulated c-fos
expression via GPR30 in breast cancer cells [28]. It is well known that
the G protein-coupled receptor activates the Akt/c-Fos signal pathway.
Therefore, it is a possible mechanism that the action of quercetin via
GPR30 could inﬂuence Akt signaling. Our results indicate that the
phosphorylation of Akt but not of MAPK is aﬀected by quercetin and
GPR30 signal pathways; however the precise mechanism remains
unknown. Akt may function in almost all the cell types; thus the
investigation of the eﬀects of agents on Akt phosphorylation may
Fig. 4. Eﬀects on signal molecules by quercetin and ligands of GPR30. A. Preosteoclasts,
which are osteoclast precursor cells, were treated for 2 days with macrophage colony-
stimulating factor (M-CSF; 20 ng/ml) and soluble receptor activator of NF-κB ligand
(sRANKL; 10 ng/ml), starved in serum-free medium for 3 h, and stimulated by M-CSF
(20 ng/ml) and sRANKL (10 ng/ml) with or without quercetin (10 μM) for the indicated
time period. After stimulation, the cells were extracted, and equal amounts of the cell
lysates were subjected to western blot analysis. B. Preosteoclasts treated as described in A
were stimulated with quercetin (10 μM) and G-1 (10 μM) or quercetin (10 μM) and G-15
(10 μM) for 15 min. The cells were extracted and equal amounts of the cell lysates were
subsequently subjected to western blot analysis.
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provide useful information.
In conclusion, the results presented in this study provide novel
insights into the eﬀects of quercetin on osteoclastogenesis, particularly
the involvement of GPR30 and the eﬀect on the phosphorylation of Akt.
Because of the direct binding of quercetin to GPR30, further investiga-
tion of quercetin and other ﬂavonoids is needed, but quercetin has the
potential to be a useful therapeutic for osteoporosis.
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